Telo Genomics Corp (TSE:TELO)
:TELO
Want to see TSE:TELO full AI Analyst Report?
TELO Stock Chart & Stats
C$0.04
C$0.01(8.00%)
At close: 4:00 PM EST
C$0.04
C$0.01(8.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.13
Previous CloseN/A
Volume60.50K
Average Volume (3M)29.30K
Market Cap
C$5.02M
Enterprise ValueC$6.14M
Total Cash (Recent Filing)C$50.11K
Total Debt (Recent Filing)C$161.31K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding100,430,470
10 Day Avg. Volume22,350
30 Day Avg. Volume29,304
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)18.74
Price to Sales (P/S)0.00
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TechnologyThe company’s proprietary telomere measurement technology is a durable strategic asset that can create barriers to entry and differentiated clinical offerings. If clinically validated and adopted, the IP-backed platform supports sustained product leverage across oncology and other telomere-relevant disease areas.
Low Absolute LeverageLow absolute debt reduces interest and near-term refinancing pressure, preserving optionality while the business develops commercial traction. With limited fixed financing costs, management can prioritize R&D or commercialization spending without heavy interest obligations, a durable financial flexibility benefit if maintained.
Improving Cash Burn TrendA reduction in TTM operating and free cash flow losses versus the prior annual period indicates improving expense control or operational efficiency. Sustained improvement extends runway and reduces near-term financing frequency, making the company's path to commercialization less reliant on immediate capital raises.
Bears Say
No Revenue / Negative Gross ProfitThe absence of recorded revenue and negative gross profit means the core offering has not yet generated commercial sales or covered direct costs. This structural deficiency makes profitability contingent on successful commercialization, regulatory/clinical adoption, and scale — risks that persist until recurring sales are proven.
Persistent Net Losses And Cash BurnSustained net losses and negative operating/free cash flow force continual reliance on external capital. Over the medium term this increases dilution and constrains strategic investments in validation, sales, or regulatory work, weakening the company's ability to execute its commercialization roadmap without material financing events.
Negative Equity / Stockholders' DeficitA stockholders' deficit is a structural balance-sheet concern that reduces borrowing capacity and raises creditor and investor scrutiny. Negative equity signals accumulated losses exceed capital, elevating insolvency and dilution risk and making future fundraising more costly or conditional absent a clear path to profitability.
Telo Genomics Corp News
TELO FAQ
What was Telo Genomics Corp’s price range in the past 12 months?
Telo Genomics Corp lowest stock price was C$0.04 and its highest was C$0.13 in the past 12 months.
What is Telo Genomics Corp’s market cap?
Telo Genomics Corp’s market cap is C$5.02M.
When is Telo Genomics Corp’s upcoming earnings report date?
Telo Genomics Corp’s upcoming earnings report date is Jun 02, 2026 which is in 10 days.
How were Telo Genomics Corp’s earnings last quarter?
Telo Genomics Corp released its earnings results on Mar 02, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Telo Genomics Corp overvalued?
According to Wall Street analysts Telo Genomics Corp’s price is currently Overvalued.
Does Telo Genomics Corp pay dividends?
Telo Genomics Corp does not currently pay dividends.
What is Telo Genomics Corp’s EPS estimate?
Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telo Genomics Corp have?
Telo Genomics Corp has 100,430,470 shares outstanding.
What happened to Telo Genomics Corp’s price movement after its last earnings report?
Telo Genomics Corp reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Telo Genomics Corp?
Currently, no hedge funds are holding shares in TSE:TELO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Telo Genomics Corp
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.
Technical Analysis
BioMark Diagnostics
―
StageZero Life Sciences Ltd
―
Kane Biotech
―
Sona Nanotech Inc
―
Avricore Health
―